Blog
Blog
AI-driven Advancements in Life Sciences
The momentum behind AI-driven advancements in life sciences has never been stronger, and this trend was spotlighted in Everest Group’s new 2025 PEAK Matrix® report, “Life Sciences AI and Analytics Services for Commercial PEAK Matrix® Assessment 2025.” Trinity Life Sciences is honored to be recognized as a Leader in this comprehensive assessment, a distinction rooted…
Filter posts by:
Blog
Are Pharma Brands Really Transformational?
How can pharma brands connect digital marketing experiences to achieve truly transformational customer engagement? Brands that are leading the way demonstrate a complete grasp of fundamental digital marketing concepts and drive innovation in the ways that they engage customers. These brands...
Blog
Learnings to Kick-Start 2025: Health Equity
Health equity continues to be a hot topic in the life sciences industry. ISPOR EU sessions addressed several key questions surrounding the impact of health equity on HTA decision-making, the methodologies that should be employed, and the opportunities and challenges of...
Blog
Maximum Fair Price Round 2: Passing the Baton
On January 20, 2025, the Centers for Medicare & Medicaid Services (CMS) announced the set of fifteen drugs targeted for the second round of Maximum Fair Price (MFP) “negotiations” under the Inflation Reduction Act (IRA). With the outcomes of the first...
Blog
Learnings to Kick-Start 2025: Climate Resilience and Environmental Sustainability
Trinity recently presented a poster on climate resilience and environmental sustainability at ISPOR EU, titled “Attitudes and Perceptions on Environmental Sustainability Efforts in the Life Sciences Industry: A Cross-Sectional Survey from HEOR and Industry Professionals.” The poster discussed results from a...
Blog
Learnings to Kick-Start 2025: Joint Clinical Assessments and Health Technology Assessments
One trend Trinity Life Sciences has observed and that was reinforced by stakeholders at ISPOR EU is the importance of evidence in healthcare decision-making. This trend was highlighted particularly in the context of joint clinical assessments (JCA) and health technology assessments...
Blog
Solving the Cell & Gene Therapy Access Puzzle in the U.S.
Cell and gene therapies (CGTs) have ushered in a new era of medicine, offering patients transformative, even potentially curative solutions, with a single treatment. Despite the clinical promise, barriers to patient access remain given administration complexity, gaps in patient outcome evidence...
